securities fraud

$CHOW crashed 84.3% after alleged market manipulation scheme using fake financial advisors. Class action lawsuit filed for September-December 2025 investors.

Class action lawsuit filed against $MEDP over missed Q4 2025 book-to-bill guidance. Stock fell 16% on February 9, 2026. Lead plaintiff deadline set for June 8, 2026.

Class action lawsuit filed against $ATRA over alleged misstatements on tabelecleucel prospects. FDA rejected drug twice; stock crashed 40-57% post-announcements.

Pomerantz LLP investigates $GDDY for potential securities fraud following disappointing 2026 guidance and 14.28% stock decline on February 25, 2026.

Class action lawsuit filed against $STLA for alleged misstatements on electrification prospects. February 2026 €22.2B reset triggered 23% stock decline; lead plaintiffs sought.

Pomerantz LLP investigates $SRE after disappointing earnings: $970M revenue miss, 50-cent guidance cut, 19% stock decline.

Pomerantz Law Firm launches investigation into $EHC following New York Times report of below-average hospital safety measures. Stock plummets 10.35%.

Immutep stock collapsed 82% after Phase III trial failure. Law firm investigates potential securities fraud regarding disclosure timing and adequacy.

Pomerantz Law Firm investigates Weis Markets securities fraud claims following February 2026 disclosure of overstated inventory requiring multi-year financial restatement, triggering 7.16% stock decline.

ADMA Biologics faces securities fraud investigation after short report alleges $20% growth claims masked 3% actual revenue decline, triggering 30% stock collapse.

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.

Law firm Robbins Geller files class action against Driven Brands for alleged securities violations involving financial statement errors. Stock plummeted 40% after February 2026 disclosure.

Pomerantz Law Firm filed class action against $AMC over alleged securities fraud regarding APE preferred equity units excluded from special dividend. Investors must act by April 20, 2026.

Pomerantz Law Firm files class action against NuScale Power over undisclosed $495M payment to ENTRA1 Energy, causing 20% stock decline and $532M quarterly loss.

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.

PomDoctor stock plummeted 91% to $0.50 from $6.09 amid pump-and-dump fraud allegations. Pomerantz Law Firm filed class action; investors have until April 6, 2026 to claim losses.

Pomerantz Law Firm filed a class action lawsuit against $ODD, alleging executives concealed algorithmic changes by major ad partner that spiked customer acquisition costs and triggered 49% stock collapse.

Pomerantz LLP files class action against Inovio Pharmaceuticals for securities fraud over false FDA claims; stock fell 24.45% in December 2025.

Kyndryl Holdings faces 55% stock collapse after SEC financial reporting investigation and executive departures. Class action lawsuit filed; deadline April 13, 2026.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.